Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김경효 | * |
dc.date.accessioned | 2016-08-28T12:08:39Z | - |
dc.date.available | 2016-08-28T12:08:39Z | - |
dc.date.issued | 2011 | * |
dc.identifier.issn | 1556-6811 | * |
dc.identifier.other | OAK-8260 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/222185 | - |
dc.description.abstract | We compared the abilities of two serological readouts, antipolysaccharide IgG antibody concentrations and opsonophagocytic activity (OPA) titers, to predict the clinical effectiveness of the 7-valent pneumococcal conjugate vaccine (7vCRM) against invasive pneumococcal disease (IPD). We also assessed the accuracy of the previously established thresholds for GlaxoSmithKline's enzyme-linked immunosorbent assay with 22F adsorption (22F-ELISA) (≥0.2 μg/ml) and OPA assay (titer, ≥8) in predicting effectiveness. We showed that following a 3-dose 7vCRM primary vaccination, the serological response rates as determined using thresholds of ≥0.2 μg/ml IgG and an OPA titer of ≥8 corresponded well with overall effectiveness against IPD. In addition, the OPA assay seemed to better predict serotype-specific effectiveness than enzyme-linked immunoassay. Finally, when applied to post-dose-2 immune responses, both thresholds also corresponded well with the overall IPD effectiveness following a 2-dose 7vCRM primary vaccination. These results support the importance of the OPA assay in evaluating immune responses to pneumococcal conjugate vaccines. Copyright © 2011 American Society for Microbiology. All Rights Reserved. | * |
dc.language | English | * |
dc.title | Prediction of pneumococcal conjugate vaccine effectiveness against invasive pneumococcal disease using opsonophagocytic activity and antibody concentrations determined by enzyme-linked immunosorbent assay with 22F adsorption | * |
dc.type | Article | * |
dc.relation.issue | 12 | * |
dc.relation.volume | 18 | * |
dc.relation.index | SCI | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 2161 | * |
dc.relation.lastpage | 2167 | * |
dc.relation.journaltitle | Clinical and Vaccine Immunology | * |
dc.identifier.doi | 10.1128/CVI.05313-11 | * |
dc.identifier.wosid | WOS:000298141500023 | * |
dc.identifier.scopusid | 2-s2.0-83455234729 | * |
dc.author.google | Schuerman L. | * |
dc.author.google | Wysocki J. | * |
dc.author.google | Tejedor J.C. | * |
dc.author.google | Knuf M. | * |
dc.author.google | Kim K.-H. | * |
dc.author.google | Poolman J. | * |
dc.contributor.scopusid | 김경효(35448653000) | * |
dc.date.modifydate | 20240301081003 | * |